Sarepta Therapeutics, Inc., a developer of innovative RNA-targeted therapeutics, entered into a credit and security agreement with MidCap Financial, a middle market-focused, specialty finance firm, that establishes a senior secured term loan facility that allows Sarepta to borrow up to $40 million at an annual rate of 7.75%, with a maturity of June 2018, subject to certain conditions and other applicable fees. Sarepta has drawn down $20 million under the facility and has the right to repay all borrowed funds and terminate the facility at any time.

Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other life threatening diseases.